TNFRSF4 and atopic eczema: A phase 2 clinical study of an anti-OX40 monoclonal antibody (KHK4083) in subjects with moderate-to-severe atopic dermatitis was recently completed (NCT03703102, ClinialTrials.gov, accessed on 10 June 2021) [13].